[{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children\u2019s Hospital Medical Center (CCHMC) Using CURE\u2019s Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic Stem Cell Tran","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recruitment Milestone Reached in Diamyd\u00ae Phase 3 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals for Cholecalciferol
Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.
Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel®. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.
CURE’s Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as Graft Versus Host Disease.